Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Lacroix

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2025
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic AssayFrançois-Clément Bidard, Grégoire Gessain, Thomas Bachelot, et al.
Annals of Surgical Oncology|September 13, 2020
Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast LesionsCatherine Uzan, Chafika Mazouni, Caroline Rossoni, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2010
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instabilityFanny Lemée, Valérie Bergoglio, Anne Fernandez-Vidal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic AssayFrançois-Clément Bidard, Grégoire Gessain, Thomas Bachelot, et al.
Genome Biology|May 22, 2015
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplificationCharlotte K Y Ng, Luciano G Martelotto, Arnaud Gauthier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptorMaud Voisin, Philippe de Medina, Arnaud Mallinger, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
Nature Communications|May 22, 2026
Tumor sialylation regulates G-CSF stability and promotes neutrophil-mediated immunosuppression in breast cancerStefan Mereiter, Gustav Jonsson, Tiago Oliveira, et al.
NPJ Breast Cancer|April 17, 2021
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohortThomas Grinda, Natacha Joyon, Amélie Lusque, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2025
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic AssayFrançois-Clément Bidard, Grégoire Gessain, Thomas Bachelot, et al.
Annals of Surgical Oncology|September 13, 2020
Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast LesionsCatherine Uzan, Chafika Mazouni, Caroline Rossoni, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2010
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instabilityFanny Lemée, Valérie Bergoglio, Anne Fernandez-Vidal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic AssayFrançois-Clément Bidard, Grégoire Gessain, Thomas Bachelot, et al.
Genome Biology|May 22, 2015
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplificationCharlotte K Y Ng, Luciano G Martelotto, Arnaud Gauthier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptorMaud Voisin, Philippe de Medina, Arnaud Mallinger, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
Nature Communications|May 22, 2026
Tumor sialylation regulates G-CSF stability and promotes neutrophil-mediated immunosuppression in breast cancerStefan Mereiter, Gustav Jonsson, Tiago Oliveira, et al.
NPJ Breast Cancer|April 17, 2021
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohortThomas Grinda, Natacha Joyon, Amélie Lusque, et al.
Pageof 12